Whilst metreleptin monotherapy supports weight loss in obese individuals, it is not clinically meaningful with a mean 1.5 kg additional weight loss over 24 weeks noted in a previous trial [87]
Safety: In September 2025, the FDA issued a statement that compounded semaglutide is risky because these products do not undergo the FDAs review for safety, effectiveness, and quality before being offered to patients
Jastreboff AM, Kaplan LM, Fras JP, et al
Gasbjerg LS, Helsted MM, Hartmann B, Jensen MH, Gabe MBN, Sparre-Ulrich AH, Veedfald S, Stensen S, Lanng AR, Bergmann NC, et al
Published research documented measurable blood glutathione elevation within 30-60 minutes of buccal administration (Buonocore et al., 2015)
Good candidates include people with nagging sports injuries, chronic tendon or ligament pain, slow postsurgical healing, or mobility limitations from longstanding wear and tear